VO 659
Alternative Names: VO 659Latest Information Update: 19 Sep 2024
At a glance
- Originator Vico Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Huntington's disease; Spinocerebellar ataxias
Most Recent Events
- 16 Sep 2024 Interim efficacy, adverse event and pharmacokinetic data from a phase I/II trial in Huntington's disease released by Vico Therapeutics
- 03 Apr 2023 Phase-I/II clinical trials in Spinocerebellar ataxias, Huntington's disease (Parenteral)
- 03 Apr 2023 Pharmacodynamics data from the preclinical study in Huntington's disease and Spinocerebellar degeneration released by Vico Therapeutics